MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films

WARREN, N.J., Nov. 9, 2010 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm^® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it has been granted U.S. patent No. 7,824,588 from the United States Patent and Trademark Office (USPTO). The patent, issued on November 2, 2010, provides intellectual property protection for the Company's film products and methods of their preparation.

A. Mark Schobel, president and chief executive officer of MonoSol Rx, stated, "Our patented PharmFilm^® and production technologies are very important to ensuring that drug containing films are manufacturable, content uniform, stable and deliver the in-vivo performance that is expected from each and every dose.  Importantly, this patent also signals to the entire pharmaceutical industry that PharmFilm® is an ideal vehicle for delivering a variety of dosage strengths and sensitive prescription drug targets, including peptides and proteins as well as small molecules."

Mr. Schobel continued, "Our patent estate continues to strategically grow thereby affording us and our partners a strong and protected product position within the market."

Keith Kendall, executive vice president and CFO of MonoSol Rx said, "We are a technology company, a partnering company and an innovator.  Our strategy is to apply our technology, alone or in combination with others, to add value to our current and prospective partners.  Continuing to innovate and thereby expand the value and applicability of our PharmFilm^® platform is critical to the success of MonoSol Rx.  As such, we invest significant time and resources to broaden and protect our intellectual property, and we believe this latest patent gives us, and by extension our partners, significant competitive advantage."

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm^® technology to deliver drugs in films. PharmFilm^® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription and over-the-counter (OTC) drug products, a pipeline of prescription formulations based on PharmFilm^® technology, and two recent FDA approvals - Zuplenz^®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone^®  sublingual film, the first combination sublingual film product for the treatment of opioid dependence.  

MonoSol Rx's commercialization strategy for all PharmFilm^® products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing.  For existing and future partners, PharmFilm^® formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration.  PharmFilm^® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).  For press releases and other company information visit www.monosolrx.com

SOURCE MonoSol Rx